A citation-based method for searching scientific literature

Ana C Silva, Diana D Lobo, Inês M Martins, Sara M Lopes, Carina Henriques, Sónia P Duarte, Jean-Cosme Dodart, Rui Jorge Nobre, Luis Pereira de Almeida. Brain 2020
Times Cited: 27







List of co-cited articles
224 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Targeting Huntingtin Expression in Patients with Huntington's Disease.
Sarah J Tabrizi, Blair R Leavitt, G Bernhard Landwehrmeyer, Edward J Wild, Carsten Saft, Roger A Barker, Nick F Blair, David Craufurd, Josef Priller, Hugh Rickards,[...]. N Engl J Med 2019
287
29

Oligonucleotide therapy mitigates disease in spinocerebellar ataxia type 3 mice.
Hayley S McLoughlin, Lauren R Moore, Ravi Chopra, Robert Komlo, Megan McKenzie, Kate G Blumenstein, Hien Zhao, Holly B Kordasiewicz, Vikram G Shakkottai, Henry L Paulson. Ann Neurol 2018
72
25

Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy.
A R La Spada, E M Wilson, D B Lubahn, A E Harding, K H Fischbeck. Nature 1991
22

Antisense oligonucleotide therapy for spinocerebellar ataxia type 2.
Daniel R Scoles, Pratap Meera, Matthew D Schneider, Sharan Paul, Warunee Dansithong, Karla P Figueroa, Gene Hung, Frank Rigo, C Frank Bennett, Thomas S Otis,[...]. Nature 2017
164
22

Spinocerebellar ataxias: prospects and challenges for therapy development.
Tetsuo Ashizawa, Gülin Öz, Henry L Paulson. Nat Rev Neurol 2018
86
22

A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity.
Martin Jinek, Krzysztof Chylinski, Ines Fonfara, Michael Hauer, Jennifer A Doudna, Emmanuelle Charpentier. Science 2012
18

Toward RNAi therapy for the polyglutamine disease Machado-Joseph disease.
Maria do Carmo Costa, Katiuska Luna-Cancalon, Svetlana Fischer, Naila S Ashraf, Michelle Ouyang, Rahil M Dharia, Lucas Martin-Fishman, Yemen Yang, Vikram G Shakkottai, Beverly L Davidson,[...]. Mol Ther 2013
72
18

Genetics, Mechanisms, and Therapeutic Progress in Polyglutamine Spinocerebellar Ataxias.
Ronald A M Buijsen, Lodewijk J A Toonen, Sarah L Gardiner, Willeke M C van Roon-Mom. Neurotherapeutics 2019
53
18

Evaluation of Antisense Oligonucleotides Targeting ATXN3 in SCA3 Mouse Models.
Lauren R Moore, Gautam Rajpal, Ian T Dillingham, Maya Qutob, Kate G Blumenstein, Danielle Gattis, Gene Hung, Holly B Kordasiewicz, Henry L Paulson, Hayley S McLoughlin. Mol Ther Nucleic Acids 2017
73
18

Spinocerebellar ataxia.
Thomas Klockgether, Caterina Mariotti, Henry L Paulson. Nat Rev Dis Primers 2019
164
18

Triplet repeat mutation length gains correlate with cell-type specific vulnerability in Huntington disease brain.
Peggy F Shelbourne, Christine Keller-McGandy, Wenya Linda Bi, Song-Ro Yoon, Louis Dubeau, Nicola J Veitch, Jean Paul Vonsattel, Nancy S Wexler, Norman Arnheim, Sarah J Augood. Hum Mol Genet 2007
127
14

Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain.
M DiFiglia, E Sapp, K O Chase, S W Davies, G P Bates, J P Vonsattel, N Aronin. Science 1997
14

Multiplex genome engineering using CRISPR/Cas systems.
Le Cong, F Ann Ran, David Cox, Shuailiang Lin, Robert Barretto, Naomi Habib, Patrick D Hsu, Xuebing Wu, Wenyan Jiang, Luciano A Marraffini,[...]. Science 2013
14

CRISPR/Cas9 Editing of the Mutant Huntingtin Allele In Vitro and In Vivo.
Alex Mas Monteys, Shauna A Ebanks, Megan S Keiser, Beverly L Davidson. Mol Ther 2017
151
14

A divalent siRNA chemical scaffold for potent and sustained modulation of gene expression throughout the central nervous system.
Julia F Alterman, Bruno M D C Godinho, Matthew R Hassler, Chantal M Ferguson, Dimas Echeverria, Ellen Sapp, Reka A Haraszti, Andrew H Coles, Faith Conroy, Rachael Miller,[...]. Nat Biotechnol 2019
52
14


Silencing neuronal mutant androgen receptor in a mouse model of spinal and bulbar muscular atrophy.
Kentaro Sahashi, Masahisa Katsuno, Gene Hung, Hiroaki Adachi, Naohide Kondo, Hideaki Nakatsuji, Genki Tohnai, Madoka Iida, C Frank Bennett, Gen Sobue. Hum Mol Genet 2015
37
14

Excitation-induced ataxin-3 aggregation in neurons from patients with Machado-Joseph disease.
Philipp Koch, Peter Breuer, Michael Peitz, Johannes Jungverdorben, Jaideep Kesavan, Daniel Poppe, Jonas Doerr, Julia Ladewig, Jerome Mertens, Thomas Tüting,[...]. Nature 2011
232
14

Antisense Oligonucleotide-Mediated Removal of the Polyglutamine Repeat in Spinocerebellar Ataxia Type 3 Mice.
Lodewijk J A Toonen, Frank Rigo, Haico van Attikum, Willeke M C van Roon-Mom. Mol Ther Nucleic Acids 2017
59
14

Antisense oligonucleotides: A primer.
Daniel R Scoles, Eric V Minikel, Stefan M Pulst. Neurol Genet 2019
67
14

CRISPR/Cas9-Targeted Deletion of Polyglutamine in Spinocerebellar Ataxia Type 3-Derived Induced Pluripotent Stem Cells.
Shuming Ouyang, Yingjun Xie, Zeyu Xiong, Yi Yang, Yexing Xian, Zhanhui Ou, Bing Song, Yuchang Chen, Yuhuan Xie, Haoxian Li,[...]. Stem Cells Dev 2018
34
14

Pathogenesis of SCA3 and implications for other polyglutamine diseases.
Hayley S McLoughlin, Lauren R Moore, Henry L Paulson. Neurobiol Dis 2020
44
14

Spinocerebellar ataxia: an update.
Roisin Sullivan, Wai Yan Yau, Emer O'Connor, Henry Houlden. J Neurol 2019
69
14

The Truncated C-terminal Fragment of Mutant ATXN3 Disrupts Mitochondria Dynamics in Spinocerebellar Ataxia Type 3 Models.
Jung-Yu Hsu, Yu-Ling Jhang, Pei-Hsun Cheng, Yu-Fan Chang, Su-Han Mao, Han-In Yang, Chia-Wei Lin, Chuan-Mu Chen, Shang-Hsun Yang. Front Mol Neurosci 2017
22
18

Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon.
Melvin M Evers, Hoang-Dai Tran, Ioannis Zalachoras, Barry A Pepers, Onno C Meijer, Johan T den Dunnen, Gert-Jan B van Ommen, Annemieke Aartsma-Rus, Willeke M C van Roon-Mom. Neurobiol Dis 2013
52
14

Antisense oligonucleotide-mediated ataxin-1 reduction prolongs survival in SCA1 mice and reveals disease-associated transcriptome profiles.
Jillian Friedrich, Holly B Kordasiewicz, Brennon O'Callaghan, Hillary P Handler, Carmen Wagener, Lisa Duvick, Eric E Swayze, Orion Rainwater, Bente Hofstra, Michael Benneyworth,[...]. JCI Insight 2018
49
14

Antisense oligonucleotides targeting mutant Ataxin-7 restore visual function in a mouse model of spinocerebellar ataxia type 7.
Chenchen Niu, Thazah P Prakash, Aneeza Kim, John L Quach, Laryssa A Huryn, Yuechen Yang, Edith Lopez, Ali Jazayeri, Gene Hung, Bryce L Sopher,[...]. Sci Transl Med 2018
42
14

Therapies targeting DNA and RNA in Huntington's disease.
Edward J Wild, Sarah J Tabrizi. Lancet Neurol 2017
137
14

Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice.
L Mangiarini, K Sathasivam, M Seller, B Cozens, A Harper, C Hetherington, M Lawton, Y Trottier, H Lehrach, S W Davies,[...]. Cell 1996
14

Double setback for ASO trials in Huntington disease.
Katie Kingwell. Nat Rev Drug Discov 2021
12
33

Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides.
Richard S Geary, Daniel Norris, Rosie Yu, C Frank Bennett. Adv Drug Deliv Rev 2015
420
11

AAV5-miHTT Gene Therapy Demonstrates Broad Distribution and Strong Human Mutant Huntingtin Lowering in a Huntington's Disease Minipig Model.
Melvin M Evers, Jana Miniarikova, Stefan Juhas, Astrid Vallès, Bozena Bohuslavova, Jana Juhasova, Helena Kupcova Skalnikova, Petr Vodicka, Ivona Valekova, Cynthia Brouwers,[...]. Mol Ther 2018
71
11

Repeat instability as the basis for human diseases and as a potential target for therapy.
Arturo López Castel, John D Cleary, Christopher E Pearson. Nat Rev Mol Cell Biol 2010
297
11


CRISPR/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington's disease.
Su Yang, Renbao Chang, Huiming Yang, Ting Zhao, Yan Hong, Ha Eun Kong, Xiaobo Sun, Zhaohui Qin, Peng Jin, Shihua Li,[...]. J Clin Invest 2017
166
11

Dramatic tissue-specific mutation length increases are an early molecular event in Huntington disease pathogenesis.
Laura Kennedy, Elizabeth Evans, Chiung-Mei Chen, Lyndsey Craven, Peter J Detloff, Margaret Ennis, Peggy F Shelbourne. Hum Mol Genet 2003
210
11

Peripheral androgen receptor gene suppression rescues disease in mouse models of spinal and bulbar muscular atrophy.
Andrew P Lieberman, Zhigang Yu, Sue Murray, Raechel Peralta, Audrey Low, Shuling Guo, Xing Xian Yu, Constanza J Cortes, C Frank Bennett, Brett P Monia,[...]. Cell Rep 2014
113
11


DNA repair pathways underlie a common genetic mechanism modulating onset in polyglutamine diseases.
Conceição Bettencourt, Davina Hensman-Moss, Michael Flower, Sarah Wiethoff, Alexis Brice, Cyril Goizet, Giovanni Stevanin, Georgios Koutsis, Georgia Karadima, Marios Panas,[...]. Ann Neurol 2016
120
11

Silencing mutant ATXN3 expression resolves molecular phenotypes in SCA3 transgenic mice.
Edgardo Rodríguez-Lebrón, Maria do Carmo Costa, Katiuska Luna-Cancalon, Therese M Peron, Svetlana Fischer, Ryan L Boudreau, Beverly L Davidson, Henry L Paulson. Mol Ther 2013
78
11

Nonallele specific silencing of ataxin-7 improves disease phenotypes in a mouse model of SCA7.
Pavitra S Ramachandran, Ryan L Boudreau, Kellie A Schaefer, Albert R La Spada, Beverly L Davidson. Mol Ther 2014
37
11

An miRNA-mediated therapy for SCA6 blocks IRES-driven translation of the CACNA1A second cistron.
Yu Miyazaki, Xiaofei Du, Shin-Ichi Muramatsu, Christopher M Gomez. Sci Transl Med 2016
37
11

Allele-specific silencing of dominant disease genes.
Victor M Miller, Haibin Xia, Ginger L Marrs, Cynthia M Gouvion, Gloria Lee, Beverly L Davidson, Henry L Paulson. Proc Natl Acad Sci U S A 2003
289
11

Suppression of Mutant Protein Expression in SCA3 and SCA1 Mice Using a CAG Repeat-Targeting Antisense Oligonucleotide.
Eleni Kourkouta, Rudie Weij, Anchel González-Barriga, Melissa Mulder, Ruurd Verheul, Sieto Bosgra, Bas Groenendaal, Jukka Puoliväli, Jussi Toivanen, Judith C T van Deutekom,[...]. Mol Ther Nucleic Acids 2019
20
15

Metabolic and Organelle Morphology Defects in Mice and Human Patients Define Spinocerebellar Ataxia Type 7 as a Mitochondrial Disease.
Jacqueline M Ward, Colleen A Stoyas, Pawel M Switonski, Farid Ichou, Weiwei Fan, Brett Collins, Christopher E Wall, Isaac Adanyeguh, Chenchen Niu, Bryce L Sopher,[...]. Cell Rep 2019
34
11

Peripheral Oxidative Stress Biomarkers in Spinocerebellar Ataxia Type 3/Machado-Joseph Disease.
Adriano M de Assis, Jonas Alex Morales Saute, Aline Longoni, Clarissa Branco Haas, Vitor Rocco Torrez, Andressa Wigner Brochier, Gabriele Nunes Souza, Gabriel Vasata Furtado, Tailise Conte Gheno, Aline Russo,[...]. Front Neurol 2017
31
11



Caffeic acid and resveratrol ameliorate cellular damage in cell and Drosophila models of spinocerebellar ataxia type 3 through upregulation of Nrf2 pathway.
Yu-Ling Wu, Jui-Chih Chang, Wei-Yong Lin, Chien-Chun Li, Mingli Hsieh, Haw-Wen Chen, Tsu-Shing Wang, Wen-Tzu Wu, Chin-San Liu, Kai-Li Liu. Free Radic Biol Med 2018
29
11

Gene Deregulation and Underlying Mechanisms in Spinocerebellar Ataxias With Polyglutamine Expansion.
Anna Niewiadomska-Cimicka, Antoine Hache, Yvon Trottier. Front Neurosci 2020
6
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.